MDM2, MDMX and p53 in oncogenesis and cancer therapy

Cited by (998)

Items 101–200 of 998

1. Targeting tumor suppressor genes for cancer therapy
   Yunhua Liu, Xiaoxiao Hu, Cecil Han, Liana Wang, Xinna Zhang, Xiaoming He, Xiongbin Lu · 2015 · BioEssays
2. The ubiquitin ligase MDM2 sustains STAT5 stability to control T cell-mediated antitumor immunity
   Jiajia Zhou, Ilona Kryczek, Shasha Li, Li Xiong, Angelo Aguilar, Shuang Wei, Sara Grove, Linda Vatan, Jiali Yu, Yijian Yan et al. · 2021 · Nature Immunology
3. Interleukin-6 derived from cancer-associated fibroblasts attenuates the p53 response to doxorubicin in prostate cancer cells
   Emarndeena Haji Cheteh, Victoria Sarne, Sophia Ceder, Julie Bianchi, Martin Augsten, Helene Rundqvist, Lars Egevad, Arne Östman, Klas G. Wiman · 2020 · Cell Death Discovery
4. Nucleolin and nucleophosmin: nucleolar proteins with multiple functions in DNA repair
   Daniel D. Scott, Marlene Oeffinger · 2016 · Biochemistry and Cell Biology
5. LACTB, a novel epigenetic silenced tumor suppressor, inhibits colorectal cancer progression by attenuating MDM2-mediated p53 ubiquitination and degradation
   Kaixuan Zeng, Xiaoxiang Chen, Xiuxiu Hu, Xiangxiang Liu, Tao Xu, Huiling Sun, Yuqin Pan, Bangshun He, Shukui Wang · 2018 · Oncogene
6. MDM2 antagonists as a novel treatment option for acute myeloid leukemia: perspectives on the therapeutic potential of idasanutlin (RG7388)
   Arushi Khurana, Danielle A. Shafer · 2019 · OncoTargets and Therapy
7. Oral idasanutlin in patients with polycythemia vera
   John O Mascarenhas, Min Lü, Heidi Kosiorek, Elizabeth Virtgaym, Lijuan Xia, Lonette Sandy, Ruben A. Mesa, Bruce E. Petersen, Noushin Rahnamay Farnoud, Vesna Najfeld et al. · 2019 · Blood
8. Small-molecule MDM2 inhibitors in clinical trials for cancer therapy
   Shuai Wang, Fen‐Er Chen · 2022 · European Journal of Medicinal Chemistry
9. Molecular Mechanisms of p53 Deregulation in Cancer: An Overview in Multiple Myeloma
   Ana Belén Herrero, Elizabeta A. Rojas, Irena Misiewicz-Krzemińska, Patryk Krzemiński, Norma Carmen Gutierrez · 2016 · International Journal of Molecular Sciences
10. Ubiquitin–proteasome system and the role of its inhibitors in cancer therapy
    Fatemeh Aliabadi, Beheshteh Sohrabi, Ebrahim Mostafavi, Hamidreza Pazoki–Toroudi, Thomas Jay Webster · 2021 · Open Biology
11. Downmodulation of Tumor Suppressor p53 by T Cell Receptor Signaling Is Critical for Antigen-Specific CD4+ T Cell Responses
    Masashi Watanabe, Kyung Duk Moon, Melanie S. Vacchio, Karen S. Hathcock, Richard J. Hodes · 2014 · Immunity
12. Molecular landscape of pancreatic cancer: implications for current clinical trials
    Gregory M. Heestand, Razelle Kurzrock · 2015 · Oncotarget
13. Combating pancreatic cancer with PI3K pathway inhibitors in the era of personalised medicine
    James R. W. Conway, David Herrmann, TR Jeffry Evans, Jennifer P. Morton, Paul Timpson · 2018 · Gut
14. Cell fate regulation governed by p53: Friends or reversible foes in cancer therapy
    Bin Song, Ping Yang, Shuyu Zhang · 2024 · 癌症：英文版
15. Gene amplification: mechanisms and involvement in cancer
    Atsuka Matsui, Tatsuya Ihara, Hiraku Suda, Hirofumi Mikami, Kentaro Semba · 2013 · BioMolecular Concepts
16. Identification of cancer sex-disparity in the functional integrity of p53 and its X chromosome network
    Haupt, Sue, Caramia, Franco, Herschtal, Alan, Soussi, Thierry, Lozano, Guillermina, Chen, Hu, Liang, Han, Speed, Terence P., Haupt, Ygal · 2019 · Nature Communications
17. Spiro-oxindoles as a Promising Class of Small Molecule Inhibitors of p53–MDM2 Interaction Useful in Targeted Cancer Therapy
    A. Gupta, Mausumi Bharadwaj, Anoop Kumar, Ravi Mehrotra · 2016 · Topics in Current Chemistry
18. Condensation of 2-((Alkylthio)(aryl)methylene)malononitrile with 1,2-Aminothiol as a Novel Bioorthogonal Reaction for Site-Specific Protein Modification and Peptide Cyclization
    Xiaoli Zheng, Zhuoru Li, Wei Gao, Xiaoting Meng, Xuefei Li, Louis Y. P. Luk, Yibing Zhao, Yu‐Hsuan Tsai, Chuanliu Wu · 2020 · Journal of the American Chemical Society
19. Chlamydia infection depends on a functional MDM2-p53 axis
    Erik González, Marion Rother, Markus Charles Kerr, Munir A. Al‐Zeer, Mohammad Abu Lubad, Mirjana Kessler, Volker Brinkmann, Alexander Loewer, Thomas F. Meyer · 2014 · Nature Communications
20. Targeting MDM2 for novel molecular therapy: Beyond oncology
    Wei Wang, Jiang‐Jiang Qin, Mehrdad Rajaei, Xin Li, Xiaoyi Yu, Courtney Hunt, Ruiwen Zhang · 2019 · Medicinal Research Reviews
21. Structure of human MDM2 complexed with RPL11 reveals the molecular basis of p53 activation
    Jiangge Zheng, Yue Lang, Qi Zhang, Di Cui, Haili Sun, Lun Jiang, Zhenhang Chen, Rui Zhang, Yina Gao, Wenli Tian et al. · 2015 · Genes & Development
22. Strukturbasierte Entwicklung von Protein‐Protein‐Interaktionsinhibitoren: Stabilisierung und Nachahmung von Peptidliganden
    Marta Pelay‐Gimeno, Adrian Glas, Oliver Koch, Tom N. Grossmann · 2015 · Angewandte Chemie
23. Small Molecule Inhibitors of MDM2-p53 and MDMX-p53 Interactions as New Cancer Therapeutics
    Yujun Zhao, Denzil Bernard, Shaomeng Wang · 2013 · Biodiscovery
24. Intravenous leiomyomatosis: an unusual intermediate between benign and malignant uterine smooth muscle tumors
    Zehra Ordulu, Marisa R. Nucci, Paola Dal Cin, Monica L. Hollowell, Christopher N. Otis, Jason L. Hornick, Peter J. Park, Tae‐Min Kim, Bradley J. Quade, Cynthia Casson Morton · 2016 · Modern Pathology
25. Aberrant regulation of FBW7 in cancer
    Lixia Wang, Xiantao Ye, Yueyong Liu, Wenyi Wei, Zhiwei Peter Wang · 2014 · Oncotarget
26. Role of p53 in the progression of gastric cancer
    Rita A. Busuttil, Giada V. Zapparoli, Sue Haupt, Christina M. Fennell, Stephen Q. Wong, Jia‐Min Pang, Elena A. Takeno, Catherine Mitchell, Natasha Di Costanzo, Stephen B. Fox et al. · 2014 · Oncotarget
27. p53/MDM2 signaling pathway in aging, senescence and tumorigenesis
    Youyi Huang, Xiaofang Che, Peter Wang, Xiujuan Qu · 2024 · Seminars in Cancer Biology
28. NFkB is essential for activin-induced colorectal cancer migration via upregulation of PI3K-MDM2 pathway
    Arundhati Jana, Nancy L. Krett, Grace Guzman, Ahmer Khalid, Özkan Özden, Jonas J. Staudacher, Jessica I. Bauer, Ron Baik, Timothy P. Carroll, Cemal Yazıcı et al. · 2017 · Oncotarget
29. Discovery of Dual Inhibitors of MDM2 and XIAP for Cancer Treatment
    Gu, Lubing, Zhang, Hailong, Liu, Tao, Zhou, Sheng, Du, Yuhong, Xiong, Jing, Yi, Sha, Qu, Cheng-Kui, Fu, Haian, Zhou, Muxiang · 2016 · Cancer Cell
30. miR-661 downregulates both Mdm2 and Mdm4 to activate p53
    Yonit Hoffman, Débora Rosa Bublik, Yitzhak Pilpel, Moshe Oren · 2013 · Cell Death and Differentiation
31. MiR-194, commonly repressed in colorectal cancer, suppresses tumor growth by regulating the MAP4K4/c-Jun/MDM2 signaling pathway
    Bo Wang, Zhanlong Shen, Zhidong Gao, Gang Zhao, Chunyou Wang, Yang� Yang, Jizhun Zhang, Yichao Yan, Chao Shen, Kewei Jiang et al. · 2015 · Cell Cycle
32. p53-dependent and p53-independent anticancer effects of different histone deacetylase inhibitors
    Jürgen Sonnemann, Christian Marx, S Becker, Susan Wittig, Chithra Devi Palani, Oliver Holger Krämer, James F. Beck · 2013 · British Journal of Cancer
33. Pharmacological reactivation of p53 in the era of precision anticancer medicine
    Amos Tuval, Charlotte Strandgren, Angelos Heldin, Mireia Palomar-Siles, Klas G. Wiman · 2023 · Nature Reviews Clinical Oncology
34. A Versatile Platform to Analyze Low-Affinity and Transient Protein-Protein Interactions in Living Cells in Real Time
    Yaocheng Li, Luo Wei Rodewald, Christian Hoppmann, Ee Tsin Wong, Sylvain Lebreton, Pavel Šafář, Marcel Pátek, Lei Wang, Kenneth F. Wertman, Geoffrey M. Wahl · 2014 · Cell Reports
35. Targeting p53-MDM2-MDMX Loop for Cancer Therapy
    Qi Zhang, Shelya X. Zeng, Hua Lu · 2014 · Sub-cellular biochemistry/Subcellular biochemistry
36. The roles of signaling pathways in SARS-CoV-2 infection; lessons learned from SARS-CoV and MERS-CoV
    Nima Hemmat, Zahra Asadzadeh, Noora Karim Ahangar, Hajar Alemohammad, Basira Najafzadeh, Afshin Derakhshani, Amir Baghbanzadeh, Hossein Bannazadeh Baghi, Darya Javadrashid, Souzan Najafi et al. · 2021 · Archives of Virology
37. Histone deacetylase 2 controls p53 and is a critical factor in tumorigenesis
    Tobias Wagner, Peter Brand, Thorsten Heinzel, Oliver Holger Krämer · 2014 · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
38. The Roles of p53 in Mitochondrial Dynamics and Cancer Metabolism: The Pendulum between Survival and Death in Breast Cancer?
    David E. Moulder, Diana Hatoum, Enoch S. E. Tay, Yiguang Lin, Eileen M. McGowan · 2018 · Cancers
39. Heterogeneity in the inter-tumor transcriptome of high risk prostate cancer
    Wyatt, Alexander W, Mo, Fan, Wang, Kendric, McConeghy, Brian, Brahmbhatt, Sonal, Jong, Lina, Mitchell, Devon M, Johnston, Rebecca L, Haegert, Anne, Li, Estelle et al. · 2014 · Genome Biology
40. Targeting Tumor Suppressor Networks for Cancer Therapeutics
    Xuning Emily Guo, Bryan Ngo, Aram Sandaldjian Modrek, Wen‐Hwa Lee · 2014 · Current Drug Targets
41. Deregulation and Targeting of TP53 Pathway in Multiple Myeloma
    Katarina Jovanović, Guillaume Escure, Jordane Demonchy, Alexandre Willaume, Zoé Van de Wyngaert, Méryem-Maud Farhat, Paul Chauvet, Thierry T.F. Facon, Bruno Quesnel, Salomon Manier · 2019 · Frontiers in Oncology
42. Enhancing the Cell Permeability of Stapled Peptides with a Cyclic Cell-Penetrating Peptide
    Patrick G. Dougherty, Jin Wen, Xiaoyan Pan, Amritendu Koley, Jian-Guo Ren, Ashweta Sahni, Ruchira Basu, Heba Salim, George Appiah Kubi, Ziqing Qian et al. · 2019 · Journal of Medicinal Chemistry
43. USP10 suppresses tumor progression by inhibiting mTOR activation in hepatocellular carcinoma
    Chang Lu, Zhen Ning, Aman Wang, Di Chen, Xiaolong Liu, Tian Xia, Dinesh Singh Tekcham, Wen Wang, Tongming Li, Xiumei Liu et al. · 2018 · Cancer Letters
44. Proximity-enabled bioreactivity to generate covalent peptide inhibitors of p53–Mdm4
    Christian Hoppmann, Lei Wang · 2016 · Chemical Communications
45. The role of MDM2 and MDM4 in breast cancer development and prevention
    Sue Haupt, Reshma Vijayakumaran, Panimaya Jeffreena Miranda, Andrew Burgess, Elgene Lim, Ygal Haupt · 2017 · Journal of Molecular Cell Biology
46. Discovery of a novel class of highly potent inhibitors of the p53–MDM2 interaction by structure-based design starting from a conformational argument
    Furet, Pascal, Masuya, Keiichi, Kallen, Joerg, Stachyra-Valat, Thérèse, Ruetz, Stephan, Guagnano, Vito, Holzer, Philipp, Mah, Robert, Stutz, Stefan, Vaupel, Andrea et al. · 2016 · Bioorganic & Medicinal Chemistry Letters
47. The Mdm network and its regulation of p53 activities: a rheostat of cancer risk
    Eischen, Christine M., Lozano, Guillermina · 2014 · Human Mutation
48. MDM2, MDM4 and EGFR Amplifications and Hyperprogression in Metastatic Acral and Mucosal Melanoma
    Andrea Forschner, Franz-Joachim Hilke, Irina Bonzheim, Axel Gschwind, German M. Demidov, Teresa Maria Santos Amaral, Stephan Ossowski, Olaf Rieß, Christopher Schroeder, Peter Martus et al. · 2020 · Cancers
49. FLT3 inhibition upregulates HDAC8 via FOXO to inactivate p53 and promote maintenance of FLT3-ITD+ acute myeloid leukemia
    Long, Jun, Jia, Ming-Yuan, Fang, Wei-Yue, Chen, Xin-Jie, Mu, Li-Li, Wang, Zhong-Yu, Shen, Yan, Xiang, Ru-Fang, Wang, Li-Ning, Wang, Ling et al. · 2020 · Blood
50. Clonal hematopoiesis driven by chromosome 1q/MDM4 trisomy defines a canonical route toward leukemia in Fanconi anemia
    Marie Sébert, Stéphanie Gachet, Thierry M Leblanc, Alix Rousseau, Olivier Bluteau, Rathana Kim, Raouf Ben Abdelali, Flore Sicre de Fontbrune, Loïc Maillard, Carèle Fédronie et al. · 2023 · Cell stem cell
51. Analysis ofMDM2Amplification: Next-Generation Sequencing of Patients With Diverse Malignancies
    Shumei Kato, Jeffrey S. Ross, Laurie M. Gay, Farshid Dayyani, Jason Roszik, Vivek Subbiah, Razelle Kurzrock · 2018 · JCO Precision Oncology
52. Peptidomimetics: A Synthetic Tool for Inhibiting Protein–Protein Interactions in Cancer
    Lloyd Mabonga, Abidemi Paul Kappo · 2019 · International Journal of Peptide Research and Therapeutics
53. Development of selective small molecule MDM2 degraders based on nutlin
    Wang, Bo, Wu, Suzhen, Liu, Jin, Yang, Ka, Xie, Haibo, Tang, Weiping · 2019 · European Journal of Medicinal Chemistry
54. Recurrent patterns of DNA copy number alterations in tumors reflect metabolic selection pressures
    Nicholas Alexander Graham, Aspram Minasyan, Anastasia Lomova, Ashley A. Cass, Nikolas G. Balanis, Michael Friedman, Shawna T. Chan, Sophie R. Zhao, Adrián Delgado, James L Go et al. · 2017 · Molecular Systems Biology
55. Breast implant-associated ALK-negative anaplastic large cell lymphoma: a case report and discussion of possible pathogenesis.
    Eva Vertes George, John Pharm, Courtney Houston, Semar Al-Quran, Grey Brian, Hui‐Jia Dong, Wang Hai, Westley H. Reeves, Li-Jun Yang · 2013 · Europe PMC (PubMed Central)
56. Nerve growth factor receptor negates the tumor suppressor p53 as a feedback regulator
    Xiang Yu Zhou, Qian Hao, Peng Liao, Shiwen Luo, Minhong Zhang, Guohui Hu, Hongbing Liu, Yi-Wei Zhang, Bo Cao, Melody Baddoo et al. · 2016 · eLife
57. The forgotten woman's cancer: vulvar squamous cell carcinoma (VSCC) and a targeted approach to therapy
    Aisling A. Clancy, Johanna N. Spaans, Johanne Ingrid Weberpals · 2016 · Annals of Oncology
58. Pharmacological reactivation of p53 as a strategy to treat cancer
    Zawacka‐Pankau, J., Selivanova, G. · 2015 · Journal of Internal Medicine
59. BTK Modulates p53 Activity to Enhance Apoptotic and Senescent Responses
    Mohammad Althubiti, Miran Rada, Jesvin Samuel, Josep M. Escorsa, Hishyar Najeeb, Koon-Guan Lee, Kong‐Peng Lam, George D.D. Jones, Nickolai A. Barlev, Salvador Macip · 2016 · Cancer Research
60. Differential Mechanisms of Cell Death Induced by HDAC Inhibitor SAHA and MDM2 Inhibitor RG7388 in MCF-7 Cells
    Umamaheswari Natarajan, Thiagarajan Venkatesan, Vijayaraghavan Radhakrishnan, Shila Samuel, Appu Rathinavelu · 2018 · Cells
61. Ubiquitin ligases in cancer: Functions and clinical potentials
    Shanshan Duan, Michele Pagano · 2021 · Cell chemical biology
62. PD-1 regulation in immune homeostasis and immunotherapy
    Minling Gao, Jie Shi, Xiangling Xiao, Yingmeng Yao, Xu Chen, Bin Wang, Jinfang Zhang · 2024 · Cancer Letters
63. Mutant TP53 Posttranslational Modifications: Challenges and Opportunities
    Thuy‐Ai Nguyen, Daniel Menéndez, Michael A. Resnick, Carl W. Anderson · 2014 · Human Mutation
64. Prolonged Idasanutlin (RG7388) Treatment Leads to the Generation of p53-Mutated Cells
    Łukasz Skalniak, Justyna Kocik-Krol, Justyna Polak, Anna Skalniak, Monika Rak, Agnieszka Wolnicka-Głubisz, Tad A. Holak · 2018 · Cancers
65. Autoantibodies against tumor-associated antigens in the early detection of lung cancer
    Liping Dai, Jun-Chieh James Tsay, Jitian Li, Ting-An Yie, John S. Munger, Harvey Ira Pass, William N. Rom, Yi Zhang, Eng M. Tan, Jian-Ying Zhang · 2016 · Lung Cancer
66. The ubiquitin ligase TRIM21 regulates mutant p53 accumulation and gain of function in cancer
    Juan Liu, Cen Zhang, Dandan Xu, Tianliang Zhang, Chun‐Yuan Chang, Jianming Wang, Jie Liu, Lanjing Zhang, Bruce George Haffty, Wei‐Xing Zong et al. · 2023 · Journal of Clinical Investigation
67. miR-339-5p regulates the p53 tumor-suppressor pathway by targeting MDM2
    Martin Jansson, Nkerorema Djodji Damas, Michael James Lees, A Jacobsen, Anders Henrik Lund · 2014 · Oncogene
68. Schedule-dependent interaction between anticancer treatments
    Sheng‐hong Chen, William C. Forrester, Galit Lahav · 2016 · Science
69. Cytotoxicity of Pyrazine-Based Cyclometalated (C^Npz^C)Au(III) Carbene Complexes: Impact of the Nature of the Ancillary Ligand on the Biological Properties
    Benoı̂t Bertrand, Julio Fernández‐Cestau, Jesus Angulo, Marco M. D. Cominetti, Zoë A. E. Waller, Mark Searcey, Maria Anne O'Connell, Manfred Bochmann · 2017 · Inorganic Chemistry
70. Complex Cartography: Regulation of E2F Transcription Factors by Cyclin F and Ubiquitin
    Michael J. Emanuele, Taylor P. Enrico, Ryan D. Mouery, Danit Wasserman, Sapir Nachum, Amit Tzur · 2020 · Trends in Cell Biology
71. Emerging Roles of SRSF3 as a Therapeutic Target for Cancer
    Zhixia Zhou, Qi Gong, Zhijuan Lin, Yin Wang, Mengkun Li, Lu Wang, Hongfei Ding, Peifeng Li · 2020 · Frontiers in Oncology
72. Exploring Protein-Peptide Recognition Pathways Using a Supervised Molecular Dynamics Approach
    Veronica Salmaso, Mattia Sturlese, Alberto Cuzzolin, Stefano Moro · 2017 · Structure
73. Lanthanide-doped nanoparticles conjugated with an anti-CD33 antibody and a p53-activating peptide for acute myeloid leukemia therapy
    F. Niu, Jin Yan, Bohan Ma, Shichao Li, Yongping Shao, Pengcheng He, Wanggang Zhang, Wangxiao He, Peter X. Ma, Wuyuan Lu · 2018 · Biomaterials
74. Dithiocarbamate-inspired side chain stapling chemistry for peptide drug design
    Xiang Li, William David Tolbert, Honggang Hu, Neelakshi Gohain, Yan Zou, F. Niu, Wangxiao He, Weirong Yuan, Jiacan Su, Marzena Pazgier et al. · 2018 · Chemical Science
75. First in class dual MDM2/MDMX inhibitor ALRN-6924 enhances antitumor efficacy of chemotherapy in TP53 wild-type hormone receptor-positive breast cancer models
    Pairawan, Seyed, Zhao, Ming, Yuca, Erkan, Annis, Allen, Evans, Kurt, Sutton, David, Carvajal, Luis, Ren, Jian-Guo, Santiago, Solimar, Guerlavais, Vincent et al. · 2021 · Breast Cancer Research
76. Genomic profile analysis of diffuse-type gastric cancers
    Yeon-Su Lee, Yun Sung Cho, Geon Kook Lee, Sunghoon Lee, Young‐Woo Kim, Sungwoong Jho, Hak‐Min Kim, Seung-Hyun Hong, Jung-Ah Hwang, Sook-young Kim et al. · 2014 · Genome biology
77. Functional significance and therapeutic implication of ring-type E3 ligases in colorectal cancer
    Leilei Liu, Chi Chun Wong, Biao Gong, Jun Qing Yu · 2017 · Oncogene
78. MDM2 and MDM4 Are Therapeutic Vulnerabilities in Malignant Rhabdoid Tumors
    Thomas P. Howard, Taylor E. Arnoff, Melinda R. Song, Andrew O. Giacomelli, Xiaofeng Wang, Andrew Lee Hong, Neekesh V. Dharia, Su Wang, Francisca Vázquez, Minh‐Tam Pham et al. · 2019 · Cancer Research
79. LincRNA-p21 knockdown reversed tumor-associated macrophages function by promoting MDM2 to antagonize* p53 activation and alleviate breast cancer development
    Lining Zhou, Yu Tian, Fang Guo, Bin Yu, Jiali Li, Huaxi Xu, Zhaoliang Su · 2020 · Cancer Immunology Immunotherapy
80. Transcription factors in colorectal cancer: molecular mechanism and therapeutic implications
    Hui Xu, Lei Liu, Weilin Li, Duowu Zou, Jun Qing Yu, Lifu Wang, Chi Chun Wong · 2020 · Oncogene
81. Inhibiting the oncogenic translation program is an effective therapeutic strategy in multiple myeloma
    Salomon Manier, Daisy Huynh, Yu Jia Shen, Jia Zhou, Timur M. Yusufzai, Karma Ziad Salem, Richard Y. Ebright, Jiantao Shi, Jihye Park, Siobhan V. Glavey et al. · 2017 · Science Translational Medicine
82. Mdmx promotes genomic instability independent of p53 and Mdm2
    Carrillo, A M, Bouska, A, Arrate, M P, Eischen, C M · 2015 · Oncogene
83. Turning chiral peptides into a racemic supraparticle to induce the self-degradation of MDM2
    Wenguang Yang, Wenjia Liu, Xiang Li, Jin Yan, Wangxiao He · 2022 · Journal of Advanced Research
84. Dysregulation of Mdm2 and Mdm4 alternative splicing underlies motor neuron death in spinal muscular atrophy
    Meaghan Van Alstyne, Christian M. Simon, S. Pablo Sardi, Lamya S. Shihabuddin, George Z. Mentis, Livio Pellizzoni · 2018 · Genes & Development
85. ArhGAP30 promotes p53 acetylation and function in colorectal cancer
    Jilin Wang, Jin Qian, Ye Hu, Xuan Kong, Haoyan Chen, Qinghua Shi, Long Jiang, Chenming Wu, Weiping Zou, Yingxuan Chen et al. · 2014 · Nature Communications
86. Anomalous Dense Liquid Condensates Host the Nucleation of Tumor Suppressor p53 Fibrils
    Mohammad S. Safari, Zhiqing Wang, Kunaal Tailor, Anatoly B. Kolomeisky, Jacinta C. Conrad, Peter G. Vekilov · 2019 · iScience
87. RETRACTED: Mutual regulation of MDM 4 and TOP 2A in cancer cell proliferation
    Tao Liu, Hailong Zhang, Sha Yi, Lubing Gu, Muxiang Zhou · 2019 · Molecular Oncology · Retracted
88. E3 ubiquitin ligases as drug targets and prognostic biomarkers in melanoma
    Kristina Bielskienė, Lida Bagdonienė, Julija Mozūraitienė, Birutė Kazbarienė, Ernestas Janulionis · 2015 · Medicina
89. Regulation of the Mdm2-p53 signaling axis in the DNA damage response and tumorigenesis
    Michael I. Carr, Stephen N. Jones · 2016 · Translational Cancer Research
90. TRIM45 functions as a tumor suppressor in the brain via its E3 ligase activity by stabilizing p53 through K63-linked ubiquitination
    Jindong Zhang, Chuanxia Zhang, Jun Cui, Jiayu Ou, Jing Han, Yunfei Qin, Feng Zhi, Rong‐Fu Wang · 2017 · Cell Death and Disease
91. Genome-scale CRISPR-Cas9 screen identifies druggable dependencies in TP53 wild-type Ewing sarcoma
    Björn Stolte, Amanda Balboni Iniguez, Neekesh V. Dharia, Amanda L. Robichaud, Amy Saur Conway, Ann M. Morgan, Gabriela Alexe, Nathan J. Schauer, Xiaoxi Liu, Gregory H. Bird et al. · 2018 · The Journal of Experimental Medicine
92. P53 in skin cancer: From a master player to a privileged target for prevention and therapy
    Joana B. Loureiro, Ana Margarida Abrantes, Paula A. Oliveira, Lucı́lia Saraiva · 2020 · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
93. microRNAs and Alu elements in the p53-Mdm2-Mdm4 regulatory network
    Yoav Hoffman, Yitzhak Pilpel, Moshe Oren · 2014 · Journal of Molecular Cell Biology
94. Regulation of p53 by Mdm2 E3 Ligase Function Is Dispensable in Embryogenesis and Development, but Essential in Response to DNA Damage
    Laura A. Tollini, Aiwen Jin, Jikyoung Park, Yanping Zhang · 2014 · Cancer Cell
95. A New World of Biomarkers and Therapeutics for Female Reproductive System and Breast Cancers: Circular RNAs
    Anh M. Tran, Ghanbar Mahmoodi Chalbatani, Léa Berland, Mireia Cruz De los Santos, P. Shalem Raj, Seyed Amir Jalali, Elahe Gharagouzloo, Cristina Ivan, Mihnea Paul Dragomir, George A. Călin · 2020 · Frontiers in Cell and Developmental Biology
96. Understanding genomics and the immune environment of penile cancer to improve therapy
    Ahmet Murat Aydın, Jad Chahoud, Jacob J. Adashek, Mounsif Azizi, Anthony Martin Magliocco, Jeffrey S. Ross, Andrea Necchi, Philippe E. Spiess · 2020 · Nature Reviews Urology
97. F-box protein FBXO31 directs degradation of MDM2 to facilitate p53-mediated growth arrest following genotoxic stress
    Sunil Kumar Malonia, Parul Dutta, Manas Kumar Santra, Michael R. Green · 2015 · Proceedings of the National Academy of Sciences
98. A genetic variant of MDM4 influences regulation by multiple microRNAs in prostate cancer
    Shane Stegeman, Leire Moya, Luke A. Selth, Amanda B. Spurdle, Judith Ann Clements, Jyotsna Batra · 2015 · Endocrine Related Cancer
99. Integrated high-throughput analysis identifies Sp1 as a crucial determinant of p53-mediated apoptosis
    H Li, Yu Zhang, Anda Ströse, Donato Tedesco, Katerina V. Gurova, Galina Selivanova · 2014 · Cell Death and Differentiation
100. Resistance mechanisms to TP53-MDM2 inhibition identified by in vivo piggyBac transposon mutagenesis screen in an Arf ^−/− mouse model
     Chapeau, Emilie A., Gembarska, Agnieszka, Durand, Eric Y., Mandon, Emeline, Estadieu, Claire, Romanet, Vincent, Wiesmann, Marion, Tiedt, Ralph, Lehar, Joseph, de Weck, Antoine et al. · 2017 · Proceedings of the National Academy of Sciences